Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Electra Therapeutics targets $977.6 million valuation in US IPO

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at wtvbam.com →

◆ Verified

Fusion42 · 15 September 2026 · Fusion42 review

Electra Therapeutics aims for a $977.6 million valuation in its US IPO to fund late-stage clinical trials for its immunological disease and cancer therapies, including the lead drug ipsoprubart.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Electra's IPO revival signals a window reopening for biotech fundraises after a slow period. You should explore pitching investors now as clinical-stage biotech funding gains traction again.

◆ Coverage

1 source · 14 Sep 2026

◆ Related on Wire

◆ Topics

Biotechipobiotechclinical-trialsimmunotherapyfundraising